SCHEMBL3963492

SCHEMBL3963492

COC(=O)c1ccc(-c2cc(Cl)ncn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
RHEB Q15382 1/20 0.45
MAP2K4 P45985 1/20 0.45
NLRP3 Q96P20 1/20 0.45
KMO O15229 3/20 0.44
KDM6B O15054 1/20 0.44
KDM5C P41229 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
KDM3A Q9Y4C1 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 2/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27997808 0.80 KDM4E (0.69) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL15534677 0.79 KMO (0.53) KDM4EKMOHPGDMAPT
SCHEMBL29445896 0.77 KMO (0.40) KDM4EALDH1A1KMOHPGDMAPT
SCHEMBL29324953 0.77 ALDH1A1 (0.48) KDM4EALDH1A1RHEBMAP2K4HPGD
SCHEMBL31056870 0.77 ALDH1A1 (0.48) KDM4EALDH1A1RHEBMAP2K4HPGD
SCHEMBL20504918 0.77 ALDH1A1 (0.52) KDM4EALDH1A1KMOHPGDMAPT
SCHEMBL4874060 0.77 NPC1 (0.57) KDM4EHPGDMAPT
SCHEMBL25002924 0.76 KDM4C (0.63) KDM4EMAP2K4KMOKDM6BKDM5C
SCHEMBL15533892 0.76 KDM4E (0.56) KDM4EALDH1A1KMOHPGDMAPT
SCHEMBL4438489 0.76 CYP1A1 (0.52) KDM4EALDH1A1MAPTTDP1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240123073-A1 NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2024-04-18 US disclosed
EP-4255568-A1 NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF Baylor College of Medicine (US) 2023-10-11 EP disclosed
WO-2022120118-A1 NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2022-06-09 WO disclosed
WO-2009034390-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2009-03-19 WO disclosed
WO-2009034390-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240123073-A1 NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF RIPK1, RIPK2, RIPK3 KDM4E 1868/4885ALDH1A1 4723/4885RHEB 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.